Obliterated by Alzheimer's failure, Neurotrope relinquishes its Nasdaq spot in reverse merger
Battered after a spectacular failure with its Alzheimer’s drug candidate, Neurotrope Biosciences is being absorbed by a privately-held company that makes an erectile dysfunction (ED) treatment.
Stendra maker Metuchen Pharmaceuticals, which was censured by the FDA last year for making misleading claims about its ED therapy, is vaulting on to the Nasdaq following the all-stock merger with Neurotrope, under a new name: Petros (the Greek word for “rock”).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.